CASSAVA SCIENCES INC

For the period ended Mar 31, 2024. Filed May 10, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 10, 2024

FLNA$0.45+0.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Financial Statements Condensed Consolidated Balance Sheets – March 31, 2024 and December 31, 2023

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited, In thousands, except share and par value data)

	March 31, 2024	December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$124,169	$121,136
Prepaid expenses and other current assets	9,830	8,497
Total current assets	133,999	129,633
Property and equipment, net	21,604	21,854
Intangible assets, net	115	176
Total assets	$155,718	$151,663
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses	$9,603	$10,573
Accrued development expense	1,797	3,037
Accrued compensation and benefits	228	200
Warrant liabilities	65,368	—
Other current liabilities	125	385
Total current liabilities	77,121	14,195
Commitments and contingencies (Notes 9, 10 and 11)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	—	—
Common stock, $0.001 par value; 120,000,000 shares authorized; 43,248,416 and 42,236,919 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	43	42
Additional paid-in capital	434,280	518,195
Accumulated deficit	(355,726)	(380,769)
Total stockholders' equity	78,597	137,468
Total liabilities and stockholders' equity	$155,718	$151,663

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.